{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:27:27Z","timestamp":1781522847805,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"DOI":"10.7759\/cureus.43903","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:10:31Z","timestamp":1692699031000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparative Safety and Efficacy of Immunosuppressive Regimens Post-Kidney Transplant: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Shahid","family":"Qayyum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Eckardt KU","year":"2009","unstructured":"Eckardt KU, Kasiske BL, Zeier MG. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009, 9:S1-155. 10.1111\/j.1600-6143.2009.02834.x","journal-title":"Am J Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-019-0507-4","article-title":"Immunosuppression after renal transplantation","volume":"12","author":"Neuwirt H","year":"2019","unstructured":"Neuwirt H, Rudnicki M, Schratzberger P, et al.. Immunosuppression after renal transplantation. Mag Eur Med Oncol. 2019, 12:216-21. 10.1007\/s12254-019-0507-4","journal-title":"Mag Eur Med Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.79","article-title":"Belatacept: a novel immunosuppressive agent for kidney transplant recipients","volume":"8","author":"Charpentier B","year":"2012","unstructured":"Charpentier B. Belatacept: a novel immunosuppressive agent for kidney transplant recipients. Expert Rev Clin Immunol. 2012, 8:719-28. 10.1586\/eci.12.79","journal-title":"Expert Rev Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15591","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label, noninferiority study","volume":"20","author":"Harland RC","year":"2020","unstructured":"Harland RC, Klintmalm G, Jensik S, et al.. Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020, 20:159-71. 10.1111\/ajt.15591","journal-title":"Am J Transplant"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen CP","year":"2005","unstructured":"Larsen CP, Pearson TC, Adams AB, et al.. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005, 5:443-53. 10.1111\/j.1600-6143.2005.00749.x","journal-title":"Am J Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12678","article-title":"Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects","volume":"14","author":"Okimura K","year":"2014","unstructured":"Okimura K, Maeta K, Kobayashi N, et al.. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014, 14:1290-9. 10.1111\/ajt.12678","journal-title":"Am J Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199512000-00019","article-title":"Rapamune (Sirolimus, rapamycin): an overview and mechanism of action","volume":"17","author":"Sehgal SN","year":"1995","unstructured":"Sehgal SN. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit. 1995, 17:660-5. 10.1097\/00007691-199512000-00019","journal-title":"Ther Drug Monit"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner GI","year":"2004","unstructured":"Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004, 43:83-95. 10.2165\/00003088-200443020-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref9","article-title":"Calcineurin inhibitors","author":"Safarini OA","year":"2022","unstructured":"Safarini OA, Keshavamurthy C, Patel P. Calcineurin inhibitors. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16502","article-title":"OPTN\/SRTR 2019 Annual Data Report: Kidney","volume":"21","author":"Hart A","year":"2021","unstructured":"Hart A, Lentine KL, Smith JM, et al.. OPTN\/SRTR 2019 Annual Data Report: Kidney. Am J Transplant. 2021, 21:21-137. 10.1111\/ajt.16502","journal-title":"Am J Transplant"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2019.08.006","article-title":"The many faces of calcineurin inhibitor toxicity-what the FK?","volume":"27","author":"Farouk SS","year":"2020","unstructured":"Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity-what the FK?. Adv Chronic Kidney Dis. 2020, 27:56-66. 10.1053\/j.ackd.2019.08.006","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000437669.93963.8E","article-title":"Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release\/MMF, tacrolimus\/MMF, and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"97","author":"Silva HT Jr","year":"2014","unstructured":"Silva HT Jr, Yang HC, Meier-Kriesche HU, Croy R, Holman J, Fitzsimmons WE, First MR. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release\/MMF, tacrolimus\/MMF, and cyclosporine\/MMF in de novo kidney transplant recipients. Transplantation. 2014, 97:636-41. 10.1097\/01.TP.0000437669.93963.8E","journal-title":"Transplantation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13679","article-title":"Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients","volume":"33","author":"Taber DJ","year":"2019","unstructured":"Taber DJ, Chokkalingam A, Su Z, Self S, Miller D, Srinivas T. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients. Clin Transplant. 2019, 33:e13679. 10.1111\/ctr.13679","journal-title":"Clin Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15688","article-title":"Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial","volume":"20","author":"Woodle ES","year":"2020","unstructured":"Woodle ES, Kaufman DB, Shields AR, et al.. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial. Am J Transplant. 2020, 20:1039-55. 10.1111\/ajt.15688","journal-title":"Am J Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson R","year":"2011","unstructured":"Ferguson R, Griny\u00f3 J, Vincenti F, et al.. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011, 11:66-76. 10.1111\/j.1600-6143.2010.03338.x","journal-title":"Am J Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual J","year":"2018","unstructured":"Pascual J, Berger SP, Witzke O, et al.. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018, 29:1979-91. 10.1681\/ASN.2018010009","journal-title":"J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data","volume":"17","author":"Qazi Y","year":"2017","unstructured":"Qazi Y, Shaffer D, Kaplan B, et al.. Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant. 2017, 17:1358-69. 10.1111\/ajt.14090","journal-title":"Am J Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik D","year":"2013","unstructured":"Cibrik D, Silva HT Jr, Vathsala A, et al.. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation. 2013, 95:933-42. 10.1097\/TP.0b013e3182848e03","journal-title":"Transplantation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx093","article-title":"De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial","volume":"32","author":"Huh KH","year":"2017","unstructured":"Huh KH, Lee JG, Ha J, et al.. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial. Nephrol Dial Transplant. 2017, 32:1415-24. 10.1093\/ndt\/gfx093","journal-title":"Nephrol Dial Transplant"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001755","article-title":"A randomized controlled clinical trial comparing belatacept with tacrolimus after de novo kidney transplantation","volume":"101","author":"de Graav GN","year":"2017","unstructured":"de Graav GN, Baan CC, Clahsen-van Groningen MC, et al.. A randomized controlled clinical trial comparing belatacept with tacrolimus after de novo kidney transplantation. Transplantation. 2017, 101:2571-81. 10.1097\/TP.0000000000001755","journal-title":"Transplantation"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.03.048","article-title":"Pilot randomized trial of tacrolimus\/everolimus vs tacrolimus\/enteric-coated mycophenolate sodium in adult, primary kidney transplant recipients at a single center","volume":"48","author":"Ciancio G","year":"2016","unstructured":"Ciancio G, Tryphonopoulos P, Gaynor JJ, et al.. Pilot randomized trial of tacrolimus\/everolimus vs tacrolimus\/enteric-coated mycophenolate sodium in adult, primary kidney transplant recipients at a single center. Transplant Proc. 2016, 48:2006-10. 10.1016\/j.transproceed.2016.03.048","journal-title":"Transplant Proc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15560","article-title":"A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation","volume":"20","author":"Vincenti F","year":"2020","unstructured":"Vincenti F, Klintmalm G, Yang H, et al.. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation. Am J Transplant. 2020, 20:172-80. 10.1111\/ajt.15560","journal-title":"Am J Transplant"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de\u00a0novo kidney transplant patients","volume":"96","author":"Sommerer C","year":"2019","unstructured":"Sommerer C, Suwelack B, Dragun D, et al.. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de\u00a0novo kidney transplant patients. Kidney Int. 2019, 96:231-44. 10.1016\/j.kint.2019.01.041","journal-title":"Kidney Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15225","article-title":"Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi\/ARB on the histology and function of renal allografts","volume":"19","author":"Cockfield SM","year":"2019","unstructured":"Cockfield SM, Wilson S, Campbell PM, et al.. Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi\/ARB on the histology and function of renal allografts. Am J Transplant. 2019, 19:1730-44. 10.1111\/ajt.15225","journal-title":"Am J Transplant"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001843","article-title":"Pharmacokinetics and clinical outcomes of generic tacrolimus (Hexal) versus branded tacrolimus in de novo kidney transplant patients: a multicenter, randomized trial","volume":"101","author":"Arns W","year":"2017","unstructured":"Arns W, Huppertz A, Rath T, et al.. Pharmacokinetics and clinical outcomes of generic tacrolimus (Hexal) versus branded tacrolimus in de novo kidney transplant patients: a multicenter, randomized trial. Transplantation. 2017, 101:2780-8. 10.1097\/TP.0000000000001843","journal-title":"Transplantation"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16152","article-title":"Avoidance of CNI and steroids using belatacept-Results of the Clinical Trials in Organ Transplantation 16 trial","volume":"20","author":"Mannon RB","year":"2020","unstructured":"Mannon RB, Armstrong B, Stock PG, et al.. Avoidance of CNI and steroids using belatacept-Results of the Clinical Trials in Organ Transplantation 16 trial. Am J Transplant. 2020, 20:3599-608. 10.1111\/ajt.16152","journal-title":"Am J Transplant"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182a203bd","article-title":"OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation","volume":"96","author":"Albano L","year":"2013","unstructured":"Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013, 96:897-903. 10.1097\/TP.0b013e3182a203bd","journal-title":"Transplantation"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318296c9d5","article-title":"Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus","volume":"96","author":"Tsuchiya T","year":"2013","unstructured":"Tsuchiya T, Ishida H, Tanabe T, Shimizu T, Honda K, Omoto K, Tanabe K. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation. 2013, 96:198-204. 10.1097\/TP.0b013e318296c9d5","journal-title":"Transplantation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.03.025","article-title":"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients","volume":"45","author":"Bechstein WO","year":"2013","unstructured":"Bechstein WO, Paczek L, Wramner L, Squifflet JP, Zygmunt AJ. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. Transplant Proc. 2013, 45:2133-40. 10.1016\/j.transproceed.2013.03.025","journal-title":"Transplant Proc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03791106","article-title":"Therapeutic monitoring of calcineurin inhibitors for the nephrologist","volume":"2","author":"Schiff J","year":"2007","unstructured":"Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007, 2:374-84. 10.2215\/CJN.03791106","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref33","article-title":"Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients","volume":"59","author":"De Geest S","year":"1995","unstructured":"De Geest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G, Vanrenterghem Y. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation. 1995, 59:340-7.","journal-title":"Transplantation"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2016.11.024","article-title":"Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients","volume":"213","author":"Taber DJ","year":"2017","unstructured":"Taber DJ, Egede LE, Baliga PK. Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients. Am J Surg. 2017, 213:666-72. 10.1016\/j.amjsurg.2016.11.024","journal-title":"Am J Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/180069-comparative-safety-and-efficacy-of-immunosuppressive-regimens-post-kidney-transplant-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:53:01Z","timestamp":1707508381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/180069-comparative-safety-and-efficacy-of-immunosuppressive-regimens-post-kidney-transplant-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.43903","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}